Sandu Pharmaceuticals files a SEBI-mandated statement confirming no deviation in the use of ₹5.34 crore raised via preferential issues.
The funds were raised in three tranches between March 2021 and an unspecified date for revamping capital and marketing infrastructure.
The Audit Committee reviewed and approved the statement, and the auditors had no comments on the fund usage.
A portion of the third tranche (₹43.36 lakh) remains unutilized in an escrow account as of March 31, 2026.